Abstract
The reversible phosphorylation of tyrosine residues in proteins, which is governed by the balanced action of protein tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs), is a key element of the signaling pathways that are involved in the control of cell proliferation. Deregulation of either of these key regulators leads to abnormal cell signaling, which is largely associated with human pathologies including cancer. This review focuses on recent studies on the role of the protein tyrosine phosphatase SHP-1 on cell-cycle regulation and its possible roles in tumour onset and progression. SHP-1 is a PTP with two SH2 domains that is expressed in haematopoietic cells and, moderately, in many other cell types, especially malignant epithelial cells. SHP-1 regulates cell proliferation, whether it is by controlling mitogenic pathways activated by receptors with tyrosine kinase activity, or by regulating components of the cell-cycle machinery such as CDK2, p27 and cyclin D1. Since several inhibitors targeting SHP-1 have demonstrated their value in cancer treatment, this phosphatase has been proposed as a therapeutic target for this pathology.
Keywords: Protein tyrosine phosphatase, p27, CDK2, cyclin D, SH2 domain, cancer, PTPN6, PTKs, pRb, TCR, cGMP
Anti-Cancer Agents in Medicinal Chemistry
Title: SHP-1 in Cell-Cycle Regulation
Volume: 11 Issue: 1
Author(s): Pilar Lopez-Ruiz, Javier Rodriguez-Ubreva, Ariel Ernesto Cariaga, Maria Alicia Cortes and Begona Colas
Affiliation:
Keywords: Protein tyrosine phosphatase, p27, CDK2, cyclin D, SH2 domain, cancer, PTPN6, PTKs, pRb, TCR, cGMP
Abstract: The reversible phosphorylation of tyrosine residues in proteins, which is governed by the balanced action of protein tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs), is a key element of the signaling pathways that are involved in the control of cell proliferation. Deregulation of either of these key regulators leads to abnormal cell signaling, which is largely associated with human pathologies including cancer. This review focuses on recent studies on the role of the protein tyrosine phosphatase SHP-1 on cell-cycle regulation and its possible roles in tumour onset and progression. SHP-1 is a PTP with two SH2 domains that is expressed in haematopoietic cells and, moderately, in many other cell types, especially malignant epithelial cells. SHP-1 regulates cell proliferation, whether it is by controlling mitogenic pathways activated by receptors with tyrosine kinase activity, or by regulating components of the cell-cycle machinery such as CDK2, p27 and cyclin D1. Since several inhibitors targeting SHP-1 have demonstrated their value in cancer treatment, this phosphatase has been proposed as a therapeutic target for this pathology.
Export Options
About this article
Cite this article as:
Lopez-Ruiz Pilar, Rodriguez-Ubreva Javier, Ernesto Cariaga Ariel, Alicia Cortes Maria and Colas Begona, SHP-1 in Cell-Cycle Regulation, Anti-Cancer Agents in Medicinal Chemistry 2011; 11 (1) . https://dx.doi.org/10.2174/187152011794941154
DOI https://dx.doi.org/10.2174/187152011794941154 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Increase in the Non-HIV-Related Deaths Among Aids Cases in the HAART Era
Current HIV Research Green Factories for Biopharmaceuticals
Current Medicinal Chemistry Novel Concepts in the Pathogenesis and Management of Pediatric Hypertension
Current Pediatric Reviews Application of Immunological Techniques (from Vaccination to Final Measurements) in Determination of Pharmaceutical Residues in Environmental Samples
Current Analytical Chemistry Novel RNAi Therapy - Intron-Derived MicroRNA Drugs
Drug Design Reviews - Online (Discontinued) Plumbagin Nanoparticles Induce Dose and pH Dependent Toxicity on Prostate Cancer Cells.
Current Drug Delivery Molecular Therapeutics of HBV
Current Gene Therapy Peptides for Diagnosis and Treatment of Colorectal Cancer
Current Medicinal Chemistry Pathobiology and Therapeutic Implications of Tumor Acidosis
Current Medicinal Chemistry Recent Advances of Kinesin Motor Inhibitors and their Clinical Progress
Reviews on Recent Clinical Trials The Use of Synthetic Oligonucleotides as Protein Inhibitors and Anticode Drugs in Cancer Therapy: Accomplishments and Limitations
Current Cancer Drug Targets Editorial (Thematic Issue: “Current Trend in Oncolytic Virus Therapy Against Cancers”)
Current Cancer Therapy Reviews Trifluoroibuprofen Inhibits α-Methylacyl Coenzyme A Racemase (AMACR/P504S), Reduces Cancer Cell Proliferation and Inhibits in vivo Tumor Growth in Aggressive Prostate Cancer Models
Anti-Cancer Agents in Medicinal Chemistry The Contractile Properties of Airway Smooth Muscle: How their Defects can be Linked to Asthmatic Airway Hyperresponsiveness?
Current Respiratory Medicine Reviews Editorial [Hot topic: A Multi-Targeted Approach for a Complex Multifaceted Disease (Guest Editors: D.W. Shineman and H.M. Fillit)]
Current Alzheimer Research Structure- and Fragment-Based Approaches to Protease Inhibition
Current Topics in Medicinal Chemistry Fungal Bioactive Compounds in Pharmaceutical Research and Development
Current Bioactive Compounds The Heat Shock Protein 90 Chaperone Complex: An Evolving Therapeutic Target
Current Cancer Drug Targets A Novel Marine Drug, SZ–685C, Induces Apoptosis of MMQ Pituitary Tumor Cells by Downregulating miR–200c
Current Medicinal Chemistry Therapeutic Value of Vitamin D as an Adjuvant Therapy in Neonates with Sepsis
Infectious Disorders - Drug Targets